Collaborative Interactions

Within DF/HCC, the Kidney Cancer Program has engaged in a wide range of collaborations across disciplines and institutions. Collaborative interactions within the Kidney Cancer Program include:

• Investigating novel immunotherapy approaches including those targeted at PD-1/PD1-L interaction

• Examing the role specialized imaging as predictive and surrogate markers of response and resistance to selective therapies.

• Identifying novel targets for RCC therapy

• Investigating to biology and treatment of other kidney tumors and hereditary RCC syndromes including Wilms, VHL Syndrome, tuberosclerosis, Birt Hogg Dube and HLRCC. 

• Identifying biomarkers for early detection of RCC and disease recurrence. 

• Identifying prognostic factors for RCC.

• Identifying predictive biomarkers to aid in therapy selection.

• Identifying mechanisms of response and resistance to standard RCC therapies

• Determining the role on minimally invasive and non-invasive treatment approaches for RCC